Pneumonia, PneumococcalPhase 4NCT02961231
Evaluation of PCV Schedules in a Naive Population in Vietnam
A Phase 4 study testing PCV 2p+1, PCV 3p+0 and PCV 1p+1 in people with Pneumonia, Pneumococcal, run by Nagasaki University at 1 site in Vietnam.
Trial summary
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci. The investigators will reduce the circulation of vaccine type pneumococci to low levels by PCV catch-up campaign; vaccinating all children less than 3… Read more about this study
- Who is it for?
- Ages 2 to 36 monthsHealthy volunteers can take part
- Conditions the study is for
- Pneumonia, Pneumococcal
- What is being tested?
- PCV 2p+1, PCV 3p+0 and PCV 1p+1
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18,652 participants
- Where
- 1 siteVietnam
- Study dates
- 1 Oct 2016to 31 Dec 2023
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 36 months
- All sexes
- Healthy volunteers accepted
- Child
Inclusion Criteria: All children living in the intervention communes in Nha Trang city, whose parents or guardian give informed consent will be eligible to receive PCV in accordance with their age.
Exclusion Criteria: Children who are not fit enough to receive national vaccination program vaccine for health reason (eg.fever, currently under medication due to illness such as pneumonia, diarrhea, etc) in accordance with Vietnam national immunization guidelines. This will be decided by the medical doctor in charge of the vaccination at commune health center in accordance with Vietnamese guideline.
Trial locations and contacts
1 site in 1 country.
About this study
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci. The investigators will reduce the circulation of vaccine type pneumococci to low levels by PCV catch-up campaign; vaccinating all children less than 3 years of age with PCV, after which the investigators will evaluate the ability of a simplified two doses regimen and an alternative one dose regimen to prevent the reintroduction of vaccine type pneumococci compared to the WHO recommended 2 doses schedule.
Read the detailed description
Background Pneumococcal conjugate vaccine (PCVs) have substantially reduced the burden of pneumococcal disease. WHO currently recommends giving PCVs as 3 doses - either 3 doses in infancy with Pentavalent vaccine (3p+0), or two doses in infancy followed by a booster around the end of the first year of life (2p+1). The 3p+0 schedule is used in many countries introducing PCV with Gavi support while several European countries are using 2p+1 schedule. However, their high price and the current recommendation for at least 3 doses to achieve full individual protection for infants, introduces a substantial financial burden. As a result, many middle income countries have not yet introduced PCVs, and low income countries that have introduced PCVs with the aid of the Gavi, the Vaccine Alliance, may not be able to sustain PCV vaccination after graduating from GAVI support.
To date PCV programs have been designed to provide optimal individual protection of the vaccinees, yet experience in developed countries indicates that herd immunity, which is generated by reducing carriage and hence transmission of vaccine serotypes in the community, controls vaccine type pneumococcal disease in vaccinated and unvaccinated individuals alike [1]. Using PCV impact on vaccine type carriage as a marker of vaccine type disease [2], the investigators will investigate the feasibility of reducing the number of infant doses in the PCV immunization schedule, to make more efficient use of herd immunity in the protection against pneumococcal disease.
Study aim and objectives Primary objective 1- The investigators will measure the effect of the 1p+1 schedule on vaccine type pneumococcal carriage and non-inferiority compared to a 2p+1 or 3p+0 schedule in (a) children aged 4-11 months, i.e. after the age of a completed primary series and before the age where they would receive a booster dose (this is the population that is most at risk for pneumococcal disease and is likely to receive less direct protection from a reduced primary series), and (b) children aged 14-24 months, i.e. after the age where a booster dose is given in the treatment arms(this is the beginning of the age period when most intense transmission of pneumococci is believed to occur).
Secondary objective 1 - The investigators will measure the effect (both direct + indirect effects) of the 0p+1 schedule against vaccine type carriage and non-inferiority against a 2p+1 or/and 3p+0 schedules respectively in (a) children aged 4-11 months, and (b) children aged 14-24 months,.
Secondary objective 2 - The investigators will measure the effect of the 1p+1 and 0p+1 schedules against vaccine type carriage and non-inferiority against a 2p+1 or 3p+0 schedules respectively among unvaccinated mothers.
Secondary Objective 3- The investigators will measure the effect of catchup vaccination effect in the community by conducting and post catchup carriage survey, 4 months after the second catchup vaccination campaign.
Secondary objective 4 - The investigators will develop mathematical models to predict the impact of 1p+1 and 0p+1 schedules against vaccine type carriage and disease in Nha Trang if introduced simultaneously to all clusters following a catch up campaign, and infer the impact of such schedules in other transmission settings.
Study site: The study will be conducted in 27 communes of Nha Trang, central Vietnam which is the capital of Khánh Hòa province and has about 400,000 inhabitants. PCV10 was recently registered in Vietnam. However, PCV is yet to be introduced into the national immunization program in Vietnam.
Study design: The investigators will conduct a PCV cluster randomized trial in 27 communes of Nha Trang city. There will be four different schedules of PCV intervention arms; 1p+1, 0p+1, 2p+1, and 3p+0 schedules. The followings are the PCV schedules that will be investigate in this study.
0p+1 - A single dose of PCV at 12 months of age
- p+1 - A two-dose schedule of PCV at 2 and 12 months of age
- p+1 - A three-dose schedule of PCV at 2, 4 and 12 months of age
- p+0 - A three dose schedule of PCV at 2, 3 and 4 months of age Communes will be considered as clusters. Six clusters for each intervention arm and 3 clusters for the unvaccinated arm will be included in the study.
Selection of PCV for the study: PCV10 has recently been registered in Vietnam and can be purchased locally, while this is not yet the case for PCV13. Therefore the investigators decided to use PCV10 for the study.
Pneumococcal carriage survey: Nasopharyngeal samples will be collected before the catchup vaccination and annually from 60 subjects per age groups (4-11mth, 14-24mth) and their mothers. The investigators will include 6 clusters for each intervention arm. Sixty subjects will be recruited from 3 age groups (60 children 4 to 11 months old, 60 children 14 to 24 months old and 120 mothers) of each clusters to achieve the primary study objectives, which accumulates to 6480 samples for each cross sectional pneumococcal carriage survey. Our carriage surveys in Nha Trang among healthy children as well as hospitalized children admitted with acute respiratory infection found similar serotype coverage for both PCV10 and PCV13 (~65% in health and ~70% in ARI children respectively)[3]. Number of cluster and sample size were calculated based on Hayes and Moulton [4].
Selection of intervention communes: The 3 communes in the north; Vinh Luong, Vinh Phuong, and Vinh Hoa will be selected as unvaccinated communes based on the geographical background. Although we will not consider these communes as controls for the study, inclusion of unvaccinated communes will provide information on potential year by year carriage due to introduction of new strains from outside of Nha Trang or from vaccinated communes in Nha Trang. The remaining 24 communes will be randomized into 4 arms: a 2p+1 arm, a 3p+0 arm, a 1p+1 arm, and a 0p+1 arm. There are 8 rural and 19 urban communes in Nha Trang City. Two rural communes and one urban commune were selected for the unvaccinated cluster so there were 6 rural and 18 urban communes left for the randomization.
Initial catchup vaccination: a catch up vaccination campaign will be done before the start of PCV vaccine introduction. Three doses of PCV10 will be administered to all children between 2 - 6 months of age with an interval of 2 months between the first and second, and 7 months between the second and the third doses. A catch up of two doses of PCV10 will be administered to all children between 7 and 18 months of age with an interval of two months between the two doses. Children between 19 and 36 months of age will receive a single dose. This is expected to quickly control circulation of vaccine serotypes in these areas. The total number of children less than 3 years of age in 24 communes is estimated to be approximately 18,000 (750 x 24). The total number of vaccine doses required is estimated to be 30,000 doses.
PCV introduction in birth cohort children: There will be 4 PCV intervention schedules; 2p+1 arm, 3p+0 arm, 1p+1 arm, and 0p+1 arm in this study. The children will receive PCV based on which cluster/communes they reside in. This PCV vaccination work will start one month after the initial catchup vaccination campaign. Based on the current census data, the investigators estimate that the birth cohort of children in each communes will be 250 and there will be a total of 6000 children to be vaccinated per year in 24 treatment communes. Vietnam National Immunization Program vaccinate DPT-HepB-Hib vaccine at 2, 3, 4months and JE vaccine at 12 months. The investigators will vaccinate PCV on the same visit with the above vaccines.
Sample collection and testing: Nasopharyngeal samples will be collected from the study subjects. The initial screening test will be conducted at Nha Trang Pasteur Institute. DNA will be extracted from the nasopharyngeal samples and screened for S.pneumoniae lytA gene by realtime PCR assay. The positive samples will be cultured, DNA extracted and then the DNA samples will be transported to MCRI for serotype determination by Microarray assay. Already standardized protocols will be used for the testing [5].
Approach and data analysis: To address primary objective and secondary objective 1, 2 \& 3 we will conduct annual cross sectional nasopharyngeal carriage surveys testing 60 children 4 to 11 months old, 60 children 14 to 24 months old and their mothers in each cluster for the presence of vaccine serotype carriage in 27 communes of Nha Trang. The comparison of the baseline and post-catchup vaccination carriage survey will reveal the effect of catchup vaccination to children <3 years of age and initial vaccination in the community. The comparison of carriage prevalence in the intervention/treatment (1p+1 or 0p+1) clusters and the gold standard (2p+1 or 3p+0) clusters respectively will allow age-group specific assessment of non-inferiority of the 1p+1 and 0p+1 schedules if compared with the 2p+1 or 3p+0 schedules respectively in regard to protection against vaccine type carriage.
Mathematical modelling analysis: Furthermore we will use the acquired data to fit a dynamic metapopulation model for pneumococcal transmission to the observed changes in pneumococcal carriage in the 27 study communes. The estimated model parameters will be used to predict the impact of PCV in a scenario where PCV had been introduced using the 1p+1 or 0p+1 schedules in all 27 communes. We will also use this framework to infer the impact of continuation with a 1p+1 or 0p+1 schedules in other transmission settings where PCVs have been in use and where high quality allows model calibration (secondary objective 4).
Severe adverse events monitoring: Preventive medicine center in Nha Trang is responsible for monitoring SAE/AE related to routine national vaccination program in Nha Trang will collaborate and support on PCV related SAE monitoring activities.
Timeline: The investigators have already received ethical approval from Nagasaki University, Nagasaki and National Institute of Hygiene and Epidemiology, Hanoi. Ministry of Health, Vietnam approval was also obtained in September 2016.
2016, October: Initial carriage study, followed by yearly carriage surveys at same month every year up to 5 years.
2017 February: First catch-up vaccination (the second and third catch-up vaccination will follow 2 months after the first dose and 7 months after the second dose) 2017 March: Start the PCV introduction in 24 communes with different schedule based on their cluster allocation. This PCV introduction will be for 5 years.
2017, June: Post-catchup carriage survey Annual cross sectional carriage surveys will be conducted in the same month with the baseline carriage survey in 2017, 2018, 2019, 2020 and 2021 respectively.
- Conditions
- Pneumonia, Pneumococcal
- Being tested
- PCV 2p+1, PCV 3p+0, PCV 1p+1, PCV 0p+1
- Keywords
- Pneumococcal conjugate vaccine, Herd immunity, Reduced dosing schedule
- Medical subject headings
- Pneumonia, Pneumococcal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PCV 2p+1Biological
Also called Synflorix
introduction of PCV in a reduced dosing 2p+1 schedule
PCV 3p+0Biological
Also called Synflorix
introduction of PCV in a reduced dosing 3p+0 schedule
PCV 1p+1Biological
Also called Synflorix
introduction of PCV in a reduced dosing 1p+1 schedule
PCV 0p+1Biological
Also called Synflorix
introduction of PCV in a reduced dosing 0p+1 schedule
| Study group | Role | What they receive |
|---|---|---|
| PCV 2p+1 | Active comparator | PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month Receives: Biological: PCV 2p+1 |
| PCV 3p+0 | Active comparator | PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months Receives: Biological: PCV 3p+0 |
| PCV 1p+1 | Experimental | PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month Receives: Biological: PCV 1p+1 |
| PCV 0p+1 | Experimental | PCV 0p+1 schedule: no primary dose, only a booster at 12 month Receives: Biological: PCV 0p+1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
vaccine type pneumococcal carriage
Vaccine type pneumococcal carriage among children receiving different PCV dose will be investigated yearly. Non-inferiority of 1p+1 dose will be compared with those receiving 2p+1/3p+0 groups.
Measured: up to 60 months after PCV intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2016 (estimated)
- Study start1 Oct 2016
- Primary completion30 Nov 2020
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Pneumonia, PneumococcalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 18,652 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nagasaki University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Hygiene and Epidemiology, Vietnam, Murdoch Childrens Research Institute, London School of Hygiene and Tropical Medicine
- Responsible party
- Principal investigator, Prof.Lay-Myint Yoshida, Nagasaki University
- Investigators
- LAYMYINT YOSHIDA, MBBS, PhD, Principal investigator, Institute of Tropical Medicine, Nagasaki University, Nagasaki
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02961231
- Sponsor's protocol ID
- OPP1139859
- Status last verified
- Apr 2024
- First submitted
- 1 Nov 2016
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
R. J. Hayes, L. H. Moulton, Cluster randomised trials (Chapman & Hall, 2009).
Satzke C, Dunne EM, Porter BD, Klugman KP, Mulholland EK; PneuCarriage project group. The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies. PLoS Med. 2015 Nov 17;12(11):e1001903; discussion e1001903. doi: 10.1371/journal.pmed.1001903. eCollection 2015 Nov.
PubMed 26575033Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004 Mar;4(3):144-54. doi: 10.1016/S1473-3099(04)00938-7.
PubMed 14998500Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. doi: 10.1371/journal.pmed.1001517. Epub 2013 Sep 24.
PubMed 24086113Vu HT, Yoshida LM, Suzuki M, Nguyen HA, Nguyen CD, Nguyen AT, Oishi K, Yamamoto T, Watanabe K, Vu TD. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J. 2011 Jan;30(1):11-8. doi: 10.1097/INF.0b013e3181f111a2.
PubMed 20686433Quilty BJ, Toizumi M, Nguyen HAT, Le LT, Le HH, Iwasaki C, Takegata M, Kitamura N, Shah MM, Nation ML, Hinds J, Zandvoort KV, Ortika BD, Dunne EM, Satzke C, Do HT, Mulholland K, Dang DA, Flasche S, Yoshida LM. Sustained and indirect effects of PCV10 reduced-dose schedules on pneumococcal carriage in Viet Nam: a long-term follow-up of a cluster-randomised controlled trial. Lancet Infect Dis. 2026 Sep;26(9):925-938. doi: 10.1016/S1473-3099(26)00172-6. Epub 2026 May 27.
PubMed 42202846Yoshida LM, Toizumi M, Nguyen HAT, Quilty BJ, Lien LT, Hoang LH, Iwasaki C, Takegata M, Kitamura N, Nation ML, Hinds J, van Zandvoort K, Ortika BD, Dunne EM, Satzke C, Do HT, Mulholland K, Flasche S, Dang DA. Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam. N Engl J Med. 2024 Nov 28;391(21):1992-2002. doi: 10.1056/NEJMoa2400007.
PubMed 39602629Yoshida LM, Flasche S, Mulholland K, Nguyen HA, Nguyen C, Toizumi M, Dang DA. Evaluation of the effect of reduced-dose pneumococcal conjugate vaccine schedules on vaccine serotype carriage in children and their caretakers in a naive population in Vietnam: Protocol for a cluster randomized non-inferiority trial. Gates Open Res. 2023 Jul 20;7:110. doi: 10.12688/gatesopenres.14742.1. eCollection 2023.
PubMed 37780234
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of PCV Schedules in a Naive Population in Vietnam
- ClinicalTrials.gov ID
- NCT02961231
- Acronym / sponsor ID
- OPP1139859
- Conditions
- Pneumonia, Pneumococcal
- Keywords
- Pneumococcal conjugate vaccine, Herd immunity, Reduced dosing schedule
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18,652 participants (actual)
- Lead sponsor
- Nagasaki UniversityUniversity, hospital or other
- Collaborators
- National Institute of Hygiene and Epidemiology, Vietnam, Murdoch Childrens Research Institute, London School of Hygiene and Tropical Medicine
- Study start
- 1 Oct 2016 (actual)
- Primary completion
- 30 Nov 2020 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 10 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci. The investigators will reduce the circulation of vaccine type pneumococci to low levels by PCV catch-up campaign; vaccinating all children less than 3 years of age with PCV, after which the investigators will evaluate the ability of a simplified two doses regimen and an alternative one dose regimen to prevent the reintroduction of vaccine type pneumococci compared to the WHO recommended 2 doses schedule.
Detailed description
Background Pneumococcal conjugate vaccine (PCVs) have substantially reduced the burden of pneumococcal disease. WHO currently recommends giving PCVs as 3 doses - either 3 doses in infancy with Pentavalent vaccine (3p+0), or two doses in infancy followed by a booster around the end of the first year of life (2p+1). The 3p+0 schedule is used in many countries introducing PCV with Gavi support while several European countries are using 2p+1 schedule. However, their high price and the current recommendation for at least 3 doses to achieve full individual protection for infants, introduces a substantial financial burden. As a result, many middle income countries have not yet introduced PCVs, and low income countries that have introduced PCVs with the aid of the Gavi, the Vaccine Alliance, may not be able to sustain PCV vaccination after graduating from GAVI support.
To date PCV programs have been designed to provide optimal individual protection of the vaccinees, yet experience in developed countries indicates that herd immunity, which is generated by reducing carriage and hence transmission of vaccine serotypes in the community, controls vaccine type pneumococcal disease in vaccinated and unvaccinated individuals alike [1]. Using PCV impact on vaccine type carriage as a marker of vaccine type disease [2], the investigators will investigate the feasibility of reducing the number of infant doses in the PCV immunization schedule, to make more efficient use of herd immunity in the protection against pneumococcal disease.
Study aim and objectives Primary objective 1- The investigators will measure the effect of the 1p+1 schedule on vaccine type pneumococcal carriage and non-inferiority compared to a 2p+1 or 3p+0 schedule in (a) children aged 4-11 months, i.e. after the age of a completed primary series and before the age where they would receive a booster dose (this is the population that is most at risk for pneumococcal disease and is likely to receive less direct protection from a reduced primary series), and (b) children aged 14-24 months, i.e. after the age where a booster dose is given in the treatment arms(this is the beginning of the age period when most intense transmission of pneumococci is believed to occur).
Secondary objective 1 - The investigators will measure the effect (both direct + indirect effects) of the 0p+1 schedule against vaccine type carriage and non-inferiority against a 2p+1 or/and 3p+0 schedules respectively in (a) children aged 4-11 months, and (b) children aged 14-24 months,.
Secondary objective 2 - The investigators will measure the effect of the 1p+1 and 0p+1 schedules against vaccine type carriage and non-inferiority against a 2p+1 or 3p+0 schedules respectively among unvaccinated mothers.
Secondary Objective 3- The investigators will measure the effect of catchup vaccination effect in the community by conducting and post catchup carriage survey, 4 months after the second catchup vaccination campaign.
Secondary objective 4 - The investigators will develop mathematical models to predict the impact of 1p+1 and 0p+1 schedules against vaccine type carriage and disease in Nha Trang if introduced simultaneously to all clusters following a catch up campaign, and infer the impact of such schedules in other transmission settings.
Study site: The study will be conducted in 27 communes of Nha Trang, central Vietnam which is the capital of Khánh Hòa province and has about 400,000 inhabitants. PCV10 was recently registered in Vietnam. However, PCV is yet to be introduced into the national immunization program in Vietnam.
Study design: The investigators will conduct a PCV cluster randomized trial in 27 communes of Nha Trang city. There will be four different schedules of PCV intervention arms; 1p+1, 0p+1, 2p+1, and 3p+0 schedules. The followings are the PCV schedules that will be investigate in this study.
0p+1 - A single dose of PCV at 12 months of age
- p+1 - A two-dose schedule of PCV at 2 and 12 months of age
- p+1 - A three-dose schedule of PCV at 2, 4 and 12 months of age
- p+0 - A three dose schedule of PCV at 2, 3 and 4 months of age Communes will be considered as clusters. Six clusters for each intervention arm and 3 clusters for the unvaccinated arm will be included in the study.
Selection of PCV for the study: PCV10 has recently been registered in Vietnam and can be purchased locally, while this is not yet the case for PCV13. Therefore the investigators decided to use PCV10 for the study.
Pneumococcal carriage survey: Nasopharyngeal samples will be collected before the catchup vaccination and annually from 60 subjects per age groups (4-11mth, 14-24mth) and their mothers. The investigators will include 6 clusters for each intervention arm. Sixty subjects will be recruited from 3 age groups (60 children 4 to 11 months old, 60 children 14 to 24 months old and 120 mothers) of each clusters to achieve the primary study objectives, which accumulates to 6480 samples for each cross sectional pneumococcal carriage survey. Our carriage surveys in Nha Trang among healthy children as well as hospitalized children admitted with acute respiratory infection found similar serotype coverage for both PCV10 and PCV13 (~65% in health and ~70% in ARI children respectively)[3]. Number of cluster and sample size were calculated based on Hayes and Moulton [4].
Selection of intervention communes: The 3 communes in the north; Vinh Luong, Vinh Phuong, and Vinh Hoa will be selected as unvaccinated communes based on the geographical background. Although we will not consider these communes as controls for the study, inclusion of unvaccinated communes will provide information on potential year by year carriage due to introduction of new strains from outside of Nha Trang or from vaccinated communes in Nha Trang. The remaining 24 communes will be randomized into 4 arms: a 2p+1 arm, a 3p+0 arm, a 1p+1 arm, and a 0p+1 arm. There are 8 rural and 19 urban communes in Nha Trang City. Two rural communes and one urban commune were selected for the unvaccinated cluster so there were 6 rural and 18 urban communes left for the randomization.
Initial catchup vaccination: a catch up vaccination campaign will be done before the start of PCV vaccine introduction. Three doses of PCV10 will be administered to all children between 2 - 6 months of age with an interval of 2 months between the first and second, and 7 months between the second and the third doses. A catch up of two doses of PCV10 will be administered to all children between 7 and 18 months of age with an interval of two months between the two doses. Children between 19 and 36 months of age will receive a single dose. This is expected to quickly control circulation of vaccine serotypes in these areas. The total number of children less than 3 years of age in 24 communes is estimated to be approximately 18,000 (750 x 24). The total number of vaccine doses required is estimated to be 30,000 doses.
PCV introduction in birth cohort children: There will be 4 PCV intervention schedules; 2p+1 arm, 3p+0 arm, 1p+1 arm, and 0p+1 arm in this study. The children will receive PCV based on which cluster/communes they reside in. This PCV vaccination work will start one month after the initial catchup vaccination campaign. Based on the current census data, the investigators estimate that the birth cohort of children in each communes will be 250 and there will be a total of 6000 children to be vaccinated per year in 24 treatment communes. Vietnam National Immunization Program vaccinate DPT-HepB-Hib vaccine at 2, 3, 4months and JE vaccine at 12 months. The investigators will vaccinate PCV on the same visit with the above vaccines.
Sample collection and testing: Nasopharyngeal samples will be collected from the study subjects. The initial screening test will be conducted at Nha Trang Pasteur Institute. DNA will be extracted from the nasopharyngeal samples and screened for S.pneumoniae lytA gene by realtime PCR assay. The positive samples will be cultured, DNA extracted and then the DNA samples will be transported to MCRI for serotype determination by Microarray assay. Already standardized protocols will be used for the testing [5].
Approach and data analysis: To address primary objective and secondary objective 1, 2 \& 3 we will conduct annual cross sectional nasopharyngeal carriage surveys testing 60 children 4 to 11 months old, 60 children 14 to 24 months old and their mothers in each cluster for the presence of vaccine serotype carriage in 27 communes of Nha Trang. The comparison of the baseline and post-catchup vaccination carriage survey will reveal the effect of catchup vaccination to children <3 years of age and initial vaccination in the community. The comparison of carriage prevalence in the intervention/treatment (1p+1 or 0p+1) clusters and the gold standard (2p+1 or 3p+0) clusters respectively will allow age-group specific assessment of non-inferiority of the 1p+1 and 0p+1 schedules if compared with the 2p+1 or 3p+0 schedules respectively in regard to protection against vaccine type carriage.
Mathematical modelling analysis: Furthermore we will use the acquired data to fit a dynamic metapopulation model for pneumococcal transmission to the observed changes in pneumococcal carriage in the 27 study communes. The estimated model parameters will be used to predict the impact of PCV in a scenario where PCV had been introduced using the 1p+1 or 0p+1 schedules in all 27 communes. We will also use this framework to infer the impact of continuation with a 1p+1 or 0p+1 schedules in other transmission settings where PCVs have been in use and where high quality allows model calibration (secondary objective 4).
Severe adverse events monitoring: Preventive medicine center in Nha Trang is responsible for monitoring SAE/AE related to routine national vaccination program in Nha Trang will collaborate and support on PCV related SAE monitoring activities.
Timeline: The investigators have already received ethical approval from Nagasaki University, Nagasaki and National Institute of Hygiene and Epidemiology, Hanoi. Ministry of Health, Vietnam approval was also obtained in September 2016.
2016, October: Initial carriage study, followed by yearly carriage surveys at same month every year up to 5 years.
2017 February: First catch-up vaccination (the second and third catch-up vaccination will follow 2 months after the first dose and 7 months after the second dose) 2017 March: Start the PCV introduction in 24 communes with different schedule based on their cluster allocation. This PCV introduction will be for 5 years.
2017, June: Post-catchup carriage survey Annual cross sectional carriage surveys will be conducted in the same month with the baseline carriage survey in 2017, 2018, 2019, 2020 and 2021 respectively.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PCV 2p+1 | Active comparator | Biological: PCV 2p+1PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month |
| PCV 3p+0 | Active comparator | Biological: PCV 3p+0PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months |
| PCV 1p+1 | Experimental | Biological: PCV 1p+1PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month |
| PCV 0p+1 | Experimental | Biological: PCV 0p+1PCV 0p+1 schedule: no primary dose, only a booster at 12 month |
Who may qualify
- Ages
- 2 to 36 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PCV 2p+1Also: Synflorixintroduction of PCV in a reduced dosing 2p+1 schedule | Biological | PCV 2p+1 |
| PCV 3p+0Also: Synflorixintroduction of PCV in a reduced dosing 3p+0 schedule | Biological | PCV 3p+0 |
| PCV 1p+1Also: Synflorixintroduction of PCV in a reduced dosing 1p+1 schedule | Biological | PCV 1p+1 |
| PCV 0p+1Also: Synflorixintroduction of PCV in a reduced dosing 0p+1 schedule | Biological | PCV 0p+1 |
Primary outcome
vaccine type pneumococcal carriage
Time frame: up to 60 months after PCV intervention
Vaccine type pneumococcal carriage among children receiving different PCV dose will be investigated yearly. Non-inferiority of 1p+1 dose will be compared with those receiving 2p+1/3p+0 groups.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
- BackgroundR. J. Hayes, L. H. Moulton, Cluster randomised trials (Chapman & Hall, 2009).
- Background: PubMed 26575033Satzke C, Dunne EM, Porter BD, Klugman KP, Mulholland EK; PneuCarriage project group. The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies. PLoS Med. 2015 Nov 17;12(11):e1001903; discussion e1001903. doi: 10.1371/journal.pmed.1001903. eCollection 2015 Nov.
- Results publication: PubMed 14998500Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004 Mar;4(3):144-54. doi: 10.1016/S1473-3099(04)00938-7.
- Results publication: PubMed 24086113Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. doi: 10.1371/journal.pmed.1001517. Epub 2013 Sep 24.
- Results publication: PubMed 20686433Vu HT, Yoshida LM, Suzuki M, Nguyen HA, Nguyen CD, Nguyen AT, Oishi K, Yamamoto T, Watanabe K, Vu TD. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J. 2011 Jan;30(1):11-8. doi: 10.1097/INF.0b013e3181f111a2.
- Derived from this study: PubMed 42202846Quilty BJ, Toizumi M, Nguyen HAT, Le LT, Le HH, Iwasaki C, Takegata M, Kitamura N, Shah MM, Nation ML, Hinds J, Zandvoort KV, Ortika BD, Dunne EM, Satzke C, Do HT, Mulholland K, Dang DA, Flasche S, Yoshida LM. Sustained and indirect effects of PCV10 reduced-dose schedules on pneumococcal carriage in Viet Nam: a long-term follow-up of a cluster-randomised controlled trial. Lancet Infect Dis. 2026 Sep;26(9):925-938. doi: 10.1016/S1473-3099(26)00172-6. Epub 2026 May 27.
- Derived from this study: PubMed 39602629Yoshida LM, Toizumi M, Nguyen HAT, Quilty BJ, Lien LT, Hoang LH, Iwasaki C, Takegata M, Kitamura N, Nation ML, Hinds J, van Zandvoort K, Ortika BD, Dunne EM, Satzke C, Do HT, Mulholland K, Flasche S, Dang DA. Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam. N Engl J Med. 2024 Nov 28;391(21):1992-2002. doi: 10.1056/NEJMoa2400007.
- Derived from this study: PubMed 37780234Yoshida LM, Flasche S, Mulholland K, Nguyen HA, Nguyen C, Toizumi M, Dang DA. Evaluation of the effect of reduced-dose pneumococcal conjugate vaccine schedules on vaccine serotype carriage in children and their caretakers in a naive population in Vietnam: Protocol for a cluster randomized non-inferiority trial. Gates Open Res. 2023 Jul 20;7:110. doi: 10.12688/gatesopenres.14742.1. eCollection 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Pneumonia, Pneumococcal
Active, not recruitingPhase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Pneumococcal Disease
Active, not recruitingPhase 1
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Pneumonia, Bacterial
Active, not recruitingObservational study
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
Community-Acquired Pneumonia (CAP)
RecruitingObservational study
Pneumonia and Pleuropneumonia in Hospitalized Children
Pneumonia, Pleural Effusion
RecruitingPhase 4
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
LAYMYINT YOSHIDA, MBBS, PhD principal investigator
Institute of Tropical Medicine, Nagasaki University, Nagasaki
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing PCV 2p+1, PCV 3p+0 and PCV 1p+1 in people with Pneumonia, Pneumococcal, run by Nagasaki University at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
vaccine type pneumococcal carriage (time frame: up to 60 months after PCV intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02961231, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.